Compare Funko Inc (FNKO) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Funko Inc vs Pfizer Inc — how do they compare? Funko Inc trades at $6.2 (market cap $346.61M), while Pfizer Inc trades at $26.55 (market cap $154.18B). The key difference: Pfizer Inc is far larger — about 444.8× Funko Inc's market cap, and Pfizer Inc pays a 6.36% dividend while Funko Inc pays none. Which is the better fit depends on your goals.
| FNKO | PFE | |
|---|---|---|
Market Cap | $346.61M | $154.18B |
Sector | Consumer Staples | Health |
52-Week High | $6.35 | $28.56 |
52-Week Low | $2.65 | $23.60 |
Enterprise Value | $567.26M | $205.67B |
Volume | — | 29,869,932 |
Dividend Yield | — | 6.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Funko (FNKO) trades at $5.88, up 11.36% today, with strong technical momentum showing bullish signals across moving averages and oscillators. The company reported improved Q2 2026 results with net sales up 7% to $207.7 million and raised adjusted EBITDA guidance, though full-year 2025 showed a net loss of $67.36 million on $908.21 million revenue. Analyst sentiment is mixed with 42.9% buy ratings, while institutional ownership remains stable.
The outlook suggests potential recovery with recent earnings beats and strategic hires, but risks include persistent negative margins, high debt levels at 32.89% debt-to-asset ratio, and competitive pressures in the collectibles market. Valuation appears reasonable with P/S of 0.35 and EV/EBITDA of 6.41, offering upside if turnaround continues.
Pfizer (PFE) trades at $26.62, down 0.45% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. The company reported three consecutive quarterly earnings beats in 2026, with Q3 2026 EPS expected at $0.79. Revenue for 2025 was $62.58 billion, with a net income margin of 12.41%, though 2026 projections show a decline to 6.8%. Positive news highlights pipeline advancements in obesity and oncology therapies.
Pfizer presents a mixed outlook: bullish technicals and analyst support contrast with declining profit margins and patent cliff risks. Investment opportunities include a solid dividend yield and catalyst-rich pipeline in 2026, but risks involve revenue volatility post-COVID and competitive pressures. The stock's current valuation at a P/E of 35.59 may limit near-term upside absent earnings acceleration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
